Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

REGN

Regeneron Pharmaceuticals, Inc

Sep 15 • 02:34PM ET

571.46

+11.46 2.05 %

Healthcare • Biotechnology • USA • NASD

Peers: AMGN BIIB GILD VRTX MRNA BMRN INCY EXEL IONS

| Held by: VTI VOO QQQ SPY IVV VTV XLV IBB JEPI COWZ

Scroll to Statements

Index	NDX, S&P 500	P/E	14.40	EPS (ttm)	39.69	Insider Own	3.64%	Shs Outstand	104.60M	Perf Week	2.33%
Market Cap	60.57B	Forward P/E	14.20	EPS next Y	40.25	Insider Trans	0.00%	Shs Float	102.13M	Perf Month	0.97%
Enterprise Value	55.78B	PEG	10.99	EPS next Q	9.65	Inst Own	86.30%	Short Float	2.77%	Perf Quarter	7.98%
Income	4.46B	P/S	4.26	EPS this Y	-13.68%	Inst Trans	-4.37%	Short Ratio	2.86	Perf Half Y	-14.31%
Sales	14.21B	P/B	2.03	EPS next Y	2.21%	ROA	12.00%	Short Interest	2.83M	Perf YTD	-19.78%
Book/sh	281.38	P/C	8.09	EPS next 5Y	1.31%	ROE	15.34%	52W High	1170.58 -51.18%	Perf Year	-49.94%
Cash/sh	70.66	P/FCF	15.72	EPS past 3/5Y	-18.94% 15.74%	ROIC	13.66%	52W Low	476.49 19.93%	Perf 3Y	-19.38%
Dividend Est.	2.98 (0.52%)	EV/EBITDA	12.49	Sales past 3/5Y	-4.04% 16.71%	Gross Margin	81.98%	Volatility	2.15% 2.79%	Perf 5Y	1.70%
Dividend TTM	2.64 (0.46%)	EV/Sales	3.92	EPS Y/Y TTM	3.58%	Oper. Margin	27.83%	ATR (14)	15.51	Perf 10Y	14.29%
Dividend Ex-Date	Aug 18, 2025	Quick Ratio	3.72	Sales Y/Y TTM	5.38%	Profit Margin	31.37%	RSI (14)	51.78	Recom	1.61
Dividend Gr. 3/5Y	- -	Current Ratio	4.60	EPS Q/Q	3.24%	SMA20	-0.48%	Beta	0.31	Target Price	727.87
Payout	0.00%	Debt/Eq	0.09	Sales Q/Q	3.62%	SMA50	1.24%	Rel Volume	0.65	Prev Close	560.00
Employees	15106	LT Debt/Eq	0.09	Earnings	Aug 01 BMO	SMA200	-7.99%	Avg Volume	989.09K	Price	571.46
IPO	Apr 02, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	52.89% 11.78%	Trades		Volume	510,705	Change	2.05%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-25	Initiated	Rothschild & Co Redburn	Buy	$890
Jun-30-25	Downgrade	Argus	Buy → Hold
May-30-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$580
May-30-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$662
May-14-25	Upgrade	Citigroup	Neutral → Buy	$700
Apr-22-25	Resumed	Cantor Fitzgerald	Overweight	$695
Feb-05-25	Upgrade	Leerink Partners	Market Perform → Outperform	$762 → $834
Jan-16-25	Downgrade	UBS	Buy → Neutral	$1130 → $738
Dec-10-24	Resumed	BofA Securities	Underperform	$565
Nov-15-24	Initiated	Wolfe Research	Outperform	$1150
Nov-14-24	Initiated	Citigroup	Neutral	$895
Sep-24-24	Downgrade	Leerink Partners	Outperform → Market Perform	$1175 → $1077
Mar-12-24	Initiated	Bernstein	Outperform	$1125
Jan-12-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$884 → $1076
Nov-09-23	Initiated	Deutsche Bank	Hold	$800
Nov-03-23	Upgrade	Raymond James	Mkt Perform → Outperform	$950
Aug-21-23	Upgrade	Canaccord Genuity	Hold → Buy	$720 → $992
Aug-21-23	Reiterated	Oppenheimer	Perform	$950 → $1050
Jun-28-23	Downgrade	Canaccord Genuity	Buy → Hold	$953 → $720
Mar-27-23	Upgrade	SVB Securities	Market Perform → Outperform	$834 → $976

Show Previous Ratings

Today 09:53AM	REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock? (Zacks)
08:15AM	BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN) (Insider Monkey)
Sep-14-25 01:17AM	BMO Capital Maintains a Buy on Regeneron Pharmaceuticals (REGN), Sets a $640 PT (Insider Monkey)
Sep-12-25 08:33AM	Maias NSCLC immunotherapy secures Phase II efficacy win (Clinical Trials Arena)
Sep-11-25 12:55PM	Phase III success for Regeneron signals pozelimab and cemdisirans entry into MG market (Clinical Trials Arena)
04:57AM	Loading…
04:57AM	Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength? (Zacks)
Sep-10-25 07:33AM	Kriya, Odyssey secure megarounds; Amgen boosts R&D leadership (BioPharma Dive)
04:00AM	Pharmas new boomtown? Why drugmakers are setting up shop in a small Swiss city. (Pharma Voice)
Sep-09-25 03:10PM	Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy (Benzinga)
12:38PM	Regenerons cat and birch allergy mAbs score in Phase III trials (Clinical Trials Arena)
12:28PM	Health Care Roundup: Market Talk (The Wall Street Journal)
07:00AM	Libtayo (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer (GlobeNewswire)
Sep-08-25 11:27AM	NKTR Shares Surge 38.2% in a Week: Here's What You Should Know (Zacks)
06:30AM	Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies (GlobeNewswire)
Sep-07-25 09:15AM	2 Beaten-Down Stocks to Buy on the Dip (Motley Fool)
10:11AM	Loading…
Sep-05-25 10:11AM	RHHBY Posts Positive Data on Vabysmo in nAMD at Euretina Congress (Zacks)
Sep-04-25 04:05PM	Regeneron Announces Updated Presentation Time for Upcoming Investor Conference (GlobeNewswire)
01:32PM	Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory (Insider Monkey)
10:48AM	SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study (Zacks)
09:10AM	Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar' (Investor's Business Daily)
Sep-03-25 11:32PM	Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best (StockStory)
11:30AM	Why Is Axsome (AXSM) Up 19.2% Since Last Earnings Report? (Zacks)
10:07AM	MRK Posts Cholesterol Drug Data, Focus Shifts Back to Its Pipeline (Zacks)
02:58AM	How Is Regenerons Stock Performance Compared to Other Pharma Stocks? (Barchart)
Sep-02-25 11:12AM	Evercore ISI Maintains a Buy on Regeneron Pharmaceuticals (REGN) With a $750 PT (Insider Monkey)
Aug-29-25 04:51AM	Regeneron Pharmaceuticals, Inc. (REGN) Confident on Odronextamab Approval After Setbacks (Insider Monkey)
Aug-28-25 05:00AM	FDA Approves Regeneron Pharmaceuticals, Inc. (REGN)'s Linvoseltamab for Multiple Myeloma (Insider Monkey)
Aug-27-25 12:06PM	Regeneron tees up myasthenia gravis drug approval after Phase III victory (Clinical Trials Arena)
09:15AM	What Are Wall Street Analysts Target Price for Regeneron Pharmaceuticals Stock? (Barchart)
Aug-26-25 11:17AM	Immuneering Stock Rises 21.7% on Supply Agreement With LLY (Zacks)
10:50AM	Loading…
10:50AM	Stock Market Today: Stocks rise despite Trump threats against Fed, tech regulation (TheStreet)
08:39AM	The FDA Extends the Review Deadlines for Two Submissions by Regeneron Pharmaceuticals (REGN) (Insider Monkey)
07:54AM	J&J earmarks $2B for Fujifilms North Carolina facility (Manufacturing Dive)
07:00AM	Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis (GlobeNewswire)
Aug-25-25 01:59PM	FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles (Benzinga)
Aug-24-25 08:45AM	2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts (Motley Fool)
Aug-22-25 05:57AM	The Zacks Analyst Blog Highlights Health Care Select Sector SPDR, SPDR S&P 500 ETF Trust, UnitedHealth, Regeneron, CVS Health and Novo Nordisk (Zacks)
Aug-21-25 11:58AM	J&J signs $2bn incumbency deal at CDMO Fujifilms new hub (Pharmaceutical Technology)
11:00AM	Is This the Right Time to Consider Healthcare ETFs? (Zacks)
09:51AM	FDA Extends Review Period of REGN's Submission for Eylea HD (Zacks)
07:24AM	Novos facility issues delay FDA decisions on Regenerons Eylea HD (Pharmaceutical Technology)
05:11AM	J&J to invest $2 billion to boost US manufacturing as drug tariffs loom (Reuters)
Aug-20-25 05:30PM	FDA Pushes Back Eylea HD Review; Regeneron Still Gains (GuruFocus.com)
11:19AM	EYLEA HD (aflibercept) Injection 8 mg Applications for Expanded U.S. Label and Prefilled Syringe Receive FDA Review Period Extension (GlobeNewswire)
10:30AM	Stock Market Today: Tech stocks are diving (and taking the S&P and Nasdaq with them) (TheStreet)
Aug-19-25 09:33AM	Will EXEL's Share Repurchase Program Boost Value for Investors? (Zacks)
Aug-15-25 10:10AM	Can Eylea HD and Dupixent Profits Revive Regeneron Stock? (Zacks)
09:20AM	Veru Announces Novel Modified-Release Oral Formulation for Enobosarm (Zacks)
06:01AM	Financial Services Roundup: Market Talk (The Wall Street Journal)
Aug-14-25 05:58PM	'Big Short' investor Burry turned more bullish on second quarter (Reuters)
06:05AM	Students Earn Top Awards at 42nd Annual Research Science Institute at MIT (GlobeNewswire)
Aug-13-25 09:05AM	Here's Why You Should Consider Buying Regeneron Pharma (REGN)'s Shares (Insider Monkey)
12:14AM	5 Insightful Analyst Questions From Regeneron's Q2 Earnings Call (StockStory)
Aug-12-25 11:43PM	REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges (StockStory)
09:10AM	Guggenheim Lifts PT on Regeneron Pharmaceuticals (REGN) to $815 From $810 (Insider Monkey)
06:36AM	Sanofi halts Praluent supply in China due to limited availability (Investing.com)
Aug-11-25 08:20PM	Regeneron Reveals The Regeneron Prize For Creative Innovation 2025 Winners (Insider Monkey)
07:00AM	Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments (PR Newswire)
Aug-08-25 11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks)
03:55AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
Aug-07-25 11:48PM	BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform (Insider Monkey)
04:05PM	Regeneron Announces Investor Conference Presentations (GlobeNewswire)
Aug-06-25 11:43AM	Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks)
10:33AM	Bayer Beats on Q2 Earnings and Sales, Raises '25 Adjusted Sales View (Zacks)
Aug-05-25 05:45PM	Analyst Report: Sanofi (Morningstar Research)
08:00AM	Cisco Reinvents Digital Resilience for the Agentic Era at Splunk .conf25 (PR Newswire)
Aug-04-25 04:30PM	Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC (linvoseltamab-gcpt) (GlobeNewswire)
11:39AM	Analyst Report: Regeneron Pharmaceuticals, Inc. (Morningstar Research)
07:36AM	Manufacturing issues at Novo facility disrupt Regeneron drug review (Pharmaceutical Technology)
Aug-03-25 06:00AM	2 Biotech Stocks That Could Soar 29% and 165% According to Wall Street's Top Analysts (Motley Fool)
Aug-01-25 03:57PM	Colgate-Palmolive, Rocket, Regeneron: Trending Tickers (Yahoo Finance Video)
12:25PM	Why Regeneron (REGN) Stock Is Trading Up Today (StockStory)
11:49AM	ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock Up (Zacks)
11:10AM	Regeneron Stock Rises on Q2 Earnings and Sales Beat, Eylea HD Sales Up (Zacks)
11:10AM	Nonfarm Payrolls Come in SIgnificantly Below Expectations (Zacks)
10:46AM	Jobs Shrink in the Summer of '25, Pre-Markets Lower (Zacks)
09:30AM	Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:22AM	Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines (Benzinga)
08:40AM	Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. (Barrons.com)
08:21AM	Regeneron posts better-than-expected Q2 results, downplays tariff impact (Reuters)
07:46AM	Regeneron shares edge higher as second quarter earnings surpass estimates (Investing.com)
07:45AM	Regeneron (REGN) Tops Q2 Earnings and Revenue Estimates (Zacks)
06:41AM	Regeneron's (NASDAQ:REGN) Q2: Strong Sales (StockStory)
06:41AM	Regeneron: Q2 Earnings Snapshot (Associated Press Finance)
06:30AM	Regeneron Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
06:19AM	Chevron and Exxon Mobil head earnings for Friday (MarketWatch)
Jul-31-25 08:33PM	Trump doubles down on Most Favored Nation plan to target drug prices (Pharmaceutical Technology)
05:25PM	Trump Talks Tough on Drug Prices but His Demands Have Softened (Barrons.com)
04:16PM	What Trump's Big Pharma CEO letters mean for drug pricing power (Yahoo Finance Video)
03:40PM	Analyst Report: Sanofi (Morningstar Research)
02:30PM	Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs (The Wall Street Journal)
02:27PM	Trump pressures 17 pharma CEOs to cut US drug prices (Reuters)
02:05PM	Trump demands largest pharma companies slash US drug prices (Bloomberg)
10:37AM	Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down (Zacks)
09:01AM	Health Care Roundup: Market Talk (The Wall Street Journal)
Jul-30-25 11:01PM	Regeneron (REGN) Q2 Earnings: What To Expect (StockStory)
07:30AM	Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025 (GlobeNewswire)
Jul-29-25 05:25PM	Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
09:15AM	Unlocking Q2 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jul-28-25 10:00AM	Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SING GEORGE L	Director	Dec 31 '24	Option Exercise	413.33	3,338	1,379,696	29,610	Jan 03 04:02 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Nov 05 04:23 PM
McCourt Marion	EVP Commercial	Nov 01 '24	Sale	844.61	1,000	844,610	12,931	Nov 05 04:23 PM
MARION E MCCOURT	Officer	Nov 01 '24	Proposed Sale	844.61	1,000	844,610		Nov 01 04:38 PM
RYAN ARTHUR F	Director	Oct 01 '24	Sale	1048.78	100	104,878	17,582	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Option Exercise	381.40	1,000	381,400	13,931	Oct 03 04:02 PM
McCourt Marion	EVP Commercial	Oct 01 '24	Sale	1054.06	1,000	1,054,060	12,931	Oct 03 04:02 PM
MARION E MCCOURT	Officer	Oct 01 '24	Proposed Sale	1054.06	1,000	1,054,060		Oct 01 04:13 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

REGN

Regeneron Pharmaceuticals, Inc

Upgrade your FINVIZ experience